OCR and Ecrins Therapeutics initiated in April 2015 a 3 years pioneering translational research program to advance human and vet oncology treatment. The project, called Dog-To-Man, has the double objective :
of using data collected from a comparative oncology study with cancer-bearing dogs to accelerate and optimize their human equivalents;
of developing a veterinary product for the treatment of sarcomas in dogs.
The first phase of the program is currently focusing on comparison (histology, molecular biology) of canine and human soft tissue sarcomas and osteosarcomas.